In ₹ Crore except Per Share Latest Annual	APLLTD FY26	AJANTPHARM FY26	IPCALAB FY26	TORNTPHARM FY26	Peer Average
Valuation — at last close
P/E	◆ 22.28×	38.86×	43.14×	70.40×	50.80× -56%
P/B	◆ 2.65×	9.10×	6.11×	18.16×	11.12× -76%
EV/EBITDA	◆ 14.47×	29.20×	25.37×	38.23×	30.93× -53%
Market Cap	₹15,034 Cr	₹41,177 Cr	₹49,230 Cr	₹1.52L Cr	₹80,905 Cr -81%
Growth
Revenue CAGR 3Y	9.12%	13.37%	◆ 15.60%	13.27%	14.08% -35%
Revenue CAGR 5Y	6.37%	◆ 13.54%	12.22%	11.80%	12.52% -49%
Net Income CAGR 3Y	25.18%	21.55%	◆ 35.20%	19.75%	25.50% -1%
Revenue YoY (latest Q)	25.66%	32.53%	20.76%	◆ 50.79%	34.69% -26%
Net Income YoY (latest Q)	12.19%	49.18%	◆ 82.18%	-9.64%	40.57% -70%
Profitability
EBITDA Margin	15.23%	25.58%	20.51%	◆ 32.61%	26.23% -42%
Net Income Margin	9.13%	◆ 19.37%	12.27%	15.29%	15.64% -42%
Return on Common Equity	12.42%	25.39%	15.20%	◆ 27.07%	22.55% -45%
Return on Capital Employed	13.88%	◆ 27.90%	16.05%	14.88%	19.61% -29%
Return on Assets	8.11%	◆ 18.91%	9.81%	7.21%	11.98% -32%
Credit & Quality
Total Debt/Equity	0.24×	◆ 0.05×	0.07×	0.84×	0.32× -25%
Interest Coverage	8.54×	◆ 75.83×	20.55×	8.94×	35.11× -76%
Scale — latest FY
Revenue / Total Income	₹7,345 Cr	₹5,453 Cr	₹9,646 Cr	₹13,980 Cr	₹9,693 Cr -24%
Net Income	₹671 Cr	₹1,056 Cr	₹1,184 Cr	₹2,138 Cr	₹1,459 Cr -54%
Total Assets	₹8,763 Cr	₹6,155 Cr	₹12,370 Cr	₹44,312 Cr	₹20,946 Cr -58%
EPS	₹34.33	₹84.53	₹44.98	₹63.92	₹64.48 -47%
Book Value per Share	₹288.72	₹361.16	₹317.85	₹247.86	₹308.96 -7%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.